Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ionic rhenocene derivatives with antitumor activity.

P Köpf-Maier1, T Klapötke

  • 1Institut für Anatomie, Freie Universität Berlin.

Cancer Chemotherapy and Pharmacology
|January 1, 1992
PubMed
Summary

Three air-stable rhenium complexes show potent antitumor activity against Ehrlich ascites tumor in mice. These novel metallocene compounds demonstrate significant potential as new cytostatic agents with high cure rates and no observed toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of 31P NMR spectroscopy in predicting the response of a xenografted human hypopharynx carcinoma to irradiation.

Journal of cancer research and clinical oncology·2000
Same author

Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.

Anticancer research·1999
Same author

The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.

In vivo (Athens, Greece)·1998
Same author

Antitumor activity of titanocene amino acid complexes.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine·1996
Same author

Antitumor activity of treosulfan in human lung carcinomas.

Cancer chemotherapy and pharmacology·1996
Same author

5-Fluorouracil metabolism and cytotoxicity after pre-treatment with methotrexate or thymidine in human hypopharynx and colon carcinoma xenografts: a 19F-nuclear magnetic resonance spectroscopy study in vivo.

Cancer chemotherapy and pharmacology·1996

Area of Science:

  • Organometallic Chemistry
  • Medicinal Chemistry
  • Oncology

Background:

  • Rhenium complexes are explored for their potential therapeutic applications.
  • Metallocene compounds, known for diverse chemical properties, are investigated for biological activity.
  • The development of novel antitumor agents is crucial for cancer treatment.

Purpose of the Study:

  • To evaluate the antitumor activity of three air-stable bis(cyclopentadienyl)rhenium derivatives.
  • To assess the efficacy and safety of these rhenium(V) complexes against Ehrlich ascites tumor.
  • To introduce a new class of metallocene compounds with potential cytostatic properties.

Main Methods:

  • Testing of three ionic bis(cyclopentadienyl)rhenium(V) complexes: [(C5H5)2-ReCl2]+Cl-, [(C5H5)2ReCl2]+[AsF6]-, and [(C5H5)2-ReCl2]+[SbF6]-.
  • Administration of complexes to female CF1 mice bearing Ehrlich ascites tumor.
  • Monitoring of cure rates, therapeutic index, general condition, and performing autopsies at day 90.

Main Results:

  • The chloro and hexafluoroarsenate rhenium complexes achieved a 100% maximal cure rate.
  • Therapeutic indices of 1.7 and 2.1 were recorded for the chloro and hexafluoroarsenate complexes, respectively.
  • No adverse effects on animal health or organ pathology were observed at therapeutic doses.

Conclusions:

  • Bis(cyclopentadienyl)rhenium derivatives represent a new class of antitumor metallocene compounds.
  • These rhenium(V) complexes exhibit significant cytostatic activity and favorable safety profiles.
  • The findings support further investigation of these compounds as potential cancer therapeutics.

Related Experiment Videos